home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

Pharma Business Strategies for Biomarkers

  July 08, 2008  
Windhover Information, Intercontinental Mark Hopkins San Francisco
December 11-12, 2008

Biomarkers are hot – central to the new pharma business strategies. With attrition rates higher and trials ever more expensive, drug companies are insisting on development biomarkers. And Big Pharma’s sharpening focus on high-value specialty products means drugs targeted with biomarkers to particular patient groups are increasingly attractive.

But biomarker strategies are far from straightforward. Getting biomarkers approved for particular drugs can add time and cost; biomarker work paid for by pioneer drugs can be exploited by follow-ons – to the pioneer’s competitive disadvantage. And dealmakers are only beginning to figure out the governance and financing rules of biomarker development. With in-depth case studies and interactive panels of experts, Windhover’s groundbreaking Pharma Business Strategies for Biomarkers will probe the strategies, dealmaking and economics of building biopharma businesses in the era of biomarkers.

Why should you participate in Windhover’s Pharma Business Strategies for Biomarkers?

  • Discover key opportunities in biomarker discovery, development and commercialization
  • Get expert advice you can apply to your business from top minds in the industry, as only Windhover can deliver
  • Hear real-life case studies on the rationale behind a company’s biomarker strategy
  • Understand new development strategies and their implications for dealmaking
  • Find out how biomarkers are being used to reduce attrition in development
  • Learn which companies demand biomarkers as requirements for dealmaking – and why
  • Find out whether a combined therapeutics/diagnostics business makes sense
  • Decide whether you should sell your own biomarker with your therapeutic, give it away …or partner with a diagnostics company
  • Discover what’s likely to happen with biomarker approvals
  • Understand how biomarkers can destroy value in an associated drug

Don’t miss this unprecedented opportunity to join other senior-level executives in discussing the business case for and against biomarker technologies, and helping determine the future application of biomarkers in this competitive environment of commercializing new products.

Seating is limited. Register online today and save.

Organized by: Windhover Information
Invited Speakers:

Merck, Pfizer, AstraZeneca, etc.

Deadline for Abstracts: December 1, 2008



203-838-4401 ext. 237

E-mail: hko@windhover.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.